Enzyme-Prodrug Strategies for Cancer Therapy

  • Roger G. Melton
  • Richard J. Knox

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Richard J. Knox, Roger G. Melton
    Pages 1-9
  3. Tom Connors
    Pages 11-37
  4. Richard J. Knox
    Pages 97-131
  5. K. A. Chester, Roger G. Melton, R. E. Hawkins
    Pages 179-198
  6. K. D. Bagshawe, M. Napier
    Pages 199-207
  7. Back Matter
    Pages 245-257

About this book


Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses the major problem in cancer chemotherapy-its lack of selectivity. Antibody delivery combined with the amplification provided by the enzymatic activation of prodrugs enables selection to be made between tumour and normal tissue. ADEPT offers a novel field of opportunities in the therapy of systemic cancer and may be a major advance for the treatment of solid tumours.
This book is the first to describe ADEPT in detail. Each chapter reviews an aspect of the immunology, enzymology, biochemistry, chemistry, and cancer chemotherapy which have been integrated into the ADEPT concept. An additional chapter describes the related approach of gene-directed enzyme prodrug therapy (GDEPT). This latter approach is still in its infancy but ADEPT has entered the clinic. The initial clinical studies with ADEPT are included and discussed in detail.


biochemistry cancer chemistry chemotherapy enzyme enzymes immunology protein proteins synthesis tissue tumor

Editors and affiliations

  • Roger G. Melton
    • 1
  • Richard J. Knox
    • 2
  1. 1.Enzacta Ltd.Porton Down, WiltshireUK
  2. 2.Imperial College School of MedicineCharing Cross CampusLondonUK

Bibliographic information

  • DOI
  • Copyright Information Kluwer Academic / Plenum Publishers, New York 1999
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-7186-1
  • Online ISBN 978-1-4615-4823-2
  • Buy this book on publisher's site